NASDAQ:ATHX - Athersys Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$1.51 +0.02 (+1.34 %)
(As of 02/22/2019 04:00 PM ET)
Previous Close$1.49
Today's Range$1.48 - $1.52
52-Week Range$1.29 - $3.09
Volume335,900 shs
Average Volume605,944 shs
Market Capitalization$214.04 million
P/E Ratio-5.21
Dividend YieldN/A
Beta0.5
Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product, which has completed Phase II study for treating patients suffering from moderate and severe ischemic stroke; that is in Phase II clinical study for treating patients with acute myocardial infarction; and, which is in Phase I/II clinical study for treating patients with acute respiratory distress syndrome, as well as that has completed Phase I clinical study for patients suffering from leukemia or various other blood-borne cancers. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients, including those suffering from serious conditions with unmet medical need. The company has license and collaboration agreements with Healios K.K. to develop and commercialize MultiStem cell therapy for ischemic stroke in Japan; RTI Surgical, Inc. to develop and commercialize biologic implants for orthopedic applications in the bone graft substitutes market; the University of Minnesota to develop MultiStem cell therapy platform; and Bristol-Myers Squibb Company to provide cell lines expressing well validated drug targets for compound screening and development. Athersys, Inc. was founded in 1995 and is headquartered in Cleveland, Ohio.

Receive ATHX News and Ratings via Email

Sign-up to receive the latest news and ratings for ATHX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ATHX
CUSIPN/A
Phone216-431-9900

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3.71 million
Book Value$0.20 per share

Profitability

Net Income$-32,240,000.00
Net Margins-108.83%

Miscellaneous

Employees66
Market Cap$214.04 million
Next Earnings Date3/14/2019 (Confirmed)
OptionableOptionable

Athersys (NASDAQ:ATHX) Frequently Asked Questions

What is Athersys' stock symbol?

Athersys trades on the NASDAQ under the ticker symbol "ATHX."

How were Athersys' earnings last quarter?

Athersys, Inc. (NASDAQ:ATHX) announced its quarterly earnings data on Tuesday, August, 7th. The biopharmaceutical company reported $0.05 EPS for the quarter, topping analysts' consensus estimates of $0.00 by $0.05. The biopharmaceutical company earned $19.39 million during the quarter, compared to analysts' expectations of $12.82 million. Athersys had a negative return on equity of 58.74% and a negative net margin of 108.83%. View Athersys' Earnings History.

When is Athersys' next earnings date?

Athersys is scheduled to release their next quarterly earnings announcement on Thursday, March 14th 2019. View Earnings Estimates for Athersys.

What price target have analysts set for ATHX?

1 brokerages have issued 12 month price objectives for Athersys' shares. Their predictions range from $8.00 to $8.00. On average, they expect Athersys' share price to reach $8.00 in the next twelve months. This suggests a possible upside of 429.8% from the stock's current price. View Analyst Price Targets for Athersys.

What is the consensus analysts' recommendation for Athersys?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Athersys in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Athersys.

Has Athersys been receiving favorable news coverage?

Headlines about ATHX stock have trended somewhat positive this week, InfoTrie reports. The research group identifies negative and positive media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Athersys earned a news impact score of 1.7 on InfoTrie's scale. They also assigned news stories about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the near future.

Who are some of Athersys' key competitors?

What other stocks do shareholders of Athersys own?

Who are Athersys' key executives?

Athersys' management team includes the folowing people:
  • Dr. Gil Van Bokkelen, Co-Founder, Chairman & CEO (Age 58)
  • Mr. William B. J. Lehmann Jr., Pres, COO & Sec. (Age 53)
  • Dr. John J. Harrington, Co-Founder, Chief Scientific Officer, Exec. VP & Director (Age 52)
  • Ms. Laura K. Campbell, Sr. VP of Fin. (Age 55)
  • Dr. Manal Morsy M.D., PH.D., Sr. VP & Head of Global Regulatory Affairs

Who are Athersys' major shareholders?

Athersys' stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (5.33%), Geode Capital Management LLC (0.98%), Northern Trust Corp (0.94%), Bank of America Corp DE (0.26%), Alps Advisors Inc. (0.23%) and California Public Employees Retirement System (0.12%). Company insiders that own Athersys stock include John J Harrington, Laura K Campbell and William Lehmann Jr. View Institutional Ownership Trends for Athersys.

Which major investors are selling Athersys stock?

ATHX stock was sold by a variety of institutional investors in the last quarter, including Two Sigma Investments LP, Northern Trust Corp, California Public Employees Retirement System, NEXT Financial Group Inc and LPL Financial LLC. Company insiders that have sold Athersys company stock in the last year include John J Harrington, Laura K Campbell and William Lehmann Jr. View Insider Buying and Selling for Athersys.

Which major investors are buying Athersys stock?

ATHX stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Bank of America Corp DE, Alps Advisors Inc., Geode Capital Management LLC, Allred Capital Management LLC, Rhumbline Advisers, Two Sigma Securities LLC and Amalgamated Bank. View Insider Buying and Selling for Athersys.

How do I buy shares of Athersys?

Shares of ATHX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Athersys' stock price today?

One share of ATHX stock can currently be purchased for approximately $1.51.

How big of a company is Athersys?

Athersys has a market capitalization of $214.04 million and generates $3.71 million in revenue each year. The biopharmaceutical company earns $-32,240,000.00 in net income (profit) each year or ($0.29) on an earnings per share basis. Athersys employs 66 workers across the globe.

What is Athersys' official website?

The official website for Athersys is http://www.athersys.com.

How can I contact Athersys?

Athersys' mailing address is 3201 CARNEGIE AVENUE, CLEVELAND OH, 44115. The biopharmaceutical company can be reached via phone at 216-431-9900 or via email at [email protected]


MarketBeat Community Rating for Athersys (NASDAQ ATHX)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  256 (Vote Outperform)
Underperform Votes:  225 (Vote Underperform)
Total Votes:  481
MarketBeat's community ratings are surveys of what our community members think about Athersys and other stocks. Vote "Outperform" if you believe ATHX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ATHX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/23/2019 by MarketBeat.com Staff

Featured Article: Futures Contract

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel